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Background: It remains unclear if individuals with Tourette syndrome (TS) or chronic tic 
disorder (CTD) have an elevated risk of subsequent substance misuse. 
Methods: In this population-based cohort study, we investigated the association between 
International Classification of Diseases (ICD) diagnoses of TS/CTD and substance misuse 
outcomes accounting for psychiatric comorbidity and familial factors. The cohort included all 
individuals living in Sweden at any time between January 1, 1973 and December 31, 2013. 
Substance misuse outcomes were defined as an ICD-code of substance use-related 
disorder or cause of death, or as a substance use-related criminal conviction in the 
nationwide registers. 
Results: The cohort included 14,277,199 individuals, of which 7,832 had a TS/CTD 
diagnosis (76.3% men). TS/CTD was associated with an increased risk of any subsequent 
substance misuse outcome (adjusted hazard ratio [aHR]=3.11, [95% CI: 2.94-3.29]), 
including alcohol-related disorder (aHR=3.45, [3.19-3.72]), drug-related disorder (aHR=6.84, 
[6.32-7.40]), substance-related criminal convictions (aHR=2.56, [2.36-2.77]), and substance-
related death (aHR=2.54, [1.83-3.52]). Excluding psychiatric comorbidities had little effect on 
the magnitude of the associations, with the exception of attention-deficit/hyperactivity 
disorder, which attenuated the risk of any substance misuse outcomes (aHR=2.00, [1.82-
2.19]). The risk of any substance misuse outcomes in individuals with TS/CTD was 
substantially attenuated but remained significant when compared to their unaffected siblings 
(aHR=1.74, [1.53-1.97]). 
Conclusions: TS/CTD were associated with various types of subsequent substance misuse 
outcomes, independently of psychiatric comorbidity and familial factors shared between 
siblings. Screening for drug and alcohol use should become part of the standard clinical 






Tourette syndrome (TS) and chronic tic disorder (CTD) are childhood-onset 
neurodevelopmental movement disorders characterized by multiple motor and/or at least 
one vocal tic persisting for more than one year (1). TS/CTD affect approximately 0.5-1% of 
the population (2). A majority of patients (70-90%) have comorbid psychiatric conditions, 
including attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder 
(OCD), autism spectrum disorders, mood disorders, and anxiety disorders (3-5). 
Despite the great personal and societal relevance, substance misuse has rarely been 
studied in the field of tic disorders, with many large cohort studies not even evaluating it (4-
6). One possible reason is that most patients with TS/CTD are seen in pediatric settings and 
not followed-up into adulthood, the period of highest risk for substance misuse (7-9). In a 
rare cross-sectional study of psychiatric comorbidity in TS (3), approximately 6% of a 
clinically ascertained sample of 948 individuals with TS had a recorded lifetime substance 
use disorder, with no differences between men and women. The prevalence of substance 
use disorder was 2.6% in TS-affected adolescents and 18.5% in adults. Therefore, a non-
negligible proportion of adults with TS may develop substance use-related problems over 
time, but large epidemiological studies with prospectively collected data and long-term 
follow-ups are needed to fully capture the risk of substance misuse in this patient group. 
Given that psychiatric comorbidity is the norm rather than the exception in TS/CTD 
(3-6) and the known association between psychiatric disorders and substance misuse, 
(10,11) the relationship between TS/CTD, psychiatric comorbidities, and substance misuse 
outcomes is likely to be complex. A plausible hypothesis is that individuals with TS/CTD 
have an elevated risk of substance misuse at least partially attributable to the psychiatric 
comorbidities. However, this needs to be confirmed in much larger patient cohorts with 
sufficient statistical power. Even if the associations were explained by comorbid conditions, it 
would not make the findings less important, as substance use disorders are still likely to 
require specific clinical attention in individuals with TS/CTD. 
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If TS/CTD were associated with increased risk of substance misuse, the next logical 
step would be to attempt to understand the underlying mechanisms. The potential 
associations could be due to etiological factors shared between the two conditions, such as 
genetic liability or shared environmental risk factors (12,13). Alternatively, the association 
could reflect causal mechanisms, meaning that TS/CTD would causally increase the risk of 
substance misuse, over and above shared genetic and environmental influences between 
the two disorders. For example, individuals with TS/CTD may use alcohol or drugs to cope 
with their tics and associated comorbidities (self-medication hypothesis) (14,15). Genetically 
informative designs, such as comparing discordant twins or siblings from the same biological 
parents, are ideally suited to evaluate these alternative hypotheses. 
In this study, we leveraged the unique Swedish population-based registers and 
identified one of the world’s largest cohorts of prospectively followed patients with TS/CTD 
to: 1) estimate the risk of alcohol- or drug-related disorders, criminal convictions, and death 
in individuals with TS/CTD at the population level, 2) establish the extent to which the 
association between TS/CTD and various types of substance misuse outcomes is explained 
by psychiatric comorbidity, and 3) investigate whether the association is influenced by 




Methods and Materials 
Study cohort 
The study cohort included all individuals living in Sweden at any time between January 1, 
1973 and December 31, 2013 identified through the Swedish Total Population Register. A 
personal identity number is assigned to each individual in Sweden at birth or immigration, 
allowing linkage between different registers (16). We linked the cohort to the National Patient 
Register (NPR), the Crime Register, the Cause of Death Register, the Migration Register, 
and the Multi-Generation Register, which can be used to link individuals with their parents, 
and thus to identify siblings (17-20). The cohort was followed up through the registers from 
1973 or the 10th birthday, whichever came last, until the end of 2013. The study was 
approved by the Regional Ethical Review Board in Stockholm. 
 
Tourette syndrome and chronic tic disorder 
We identified individuals with a lifetime diagnosis of TS or CTD registered between 1973 and 
2013 from the NPR, which covers inpatient (1973–) and outpatient (2001–) International 
Classification of Diseases (ICD) diagnoses nationwide. Diagnoses of TS/CTD were 
ascertained using the Swedish versions of the ICD-8 (306.2), ICD-9 (307C), and ICD-10 
(transient tic disorder: F95.0, chronic motor or vocal tic disorder: F95.1, Tourette syndrome: 
F95.2, other tic disorders: F95.8, or unspecified tic disorder: F95.9). We used an algorithm to 
minimize the inclusion of individuals with only transient tics and excluded diagnoses 
registered before the age of three to further minimize the risk of misdiagnosis (21-23). The 
validity and reliability of the ICD codes for TS/CTD in the NPR are excellent but clinicians 
tend to use the TS and CTD codes interchangeably, precluding separate analyses for these 
tic disorder subtypes (24). 
 
Substance misuse outcomes 
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We defined substance misuse outcomes as any ICD-8, ICD-9, or ICD-10 codes for the 
diagnoses of mental and behavioral disorders due to psychoactive substance use, 
alcohol/drug-related somatic conditions, or poisoning by alcohol or drugs, registered 
between 1973 and 2013 in the NPR (diagnostic codes in Table S1). We also included 
alcohol/drug-related deaths and criminal convictions from the registers. Causes of death 
consisted of ICD codes for acute intoxication and poisoning due to alcohol or drugs, and 
alcohol- or drug-related somatic conditions (Table S2). To ensure the validity of the 
outcomes, we excluded registrations before age 10. Alcohol/drug-related criminal 
convictions were retrieved from the Crime Register, including driving under the influence of 
alcohol/drugs and violations of the Narcotic Drugs Act such as possession, manufacturing, 




To investigate whether psychiatric comorbidities contributed to the risk of substance misuse 
outcomes, we included lifetime diagnoses of the following psychiatric disorders or groups of 
disorders from the NPR: 1) ADHD, 2) conduct disorders, 3) pervasive developmental 
disorders, 4) OCD, 5) anxiety disorders, 6) depressive disorders, and 7) psychotic and 
bipolar disorders (Table S3). 
 
Statistical analyses 
For aim 1, we used Cox proportional hazards regression, with age in years as the underlying 
time-scale, to estimate the association between lifetime TS/CTD and different substance 
misuse outcomes. The risk of alcohol/drug-related disorders (any disorder and specific 
alcohol/drug-use disorders), alcohol/drug-related criminal convictions, and alcohol/drug-
related deaths in individuals with TS/CTD was compared to that of unaffected individuals in 
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the general population. Participants were followed up from 1973 or their 10th birthday, 
whichever occurred last, until the date of first substance misuse outcome, emigration, death, 
or December 31, 2013, whichever occurred first. All models were adjusted for sex and birth 
year. We present estimates both for the full sample and separately for men and women. 
In order to ensure that the observed associations were not biased due to lack of data 
coverage (e.g., exposure/outcome occurring before the start of the follow-up), we repeated 
the main analyses in a sub-cohort of individuals born after 1972 with follow-up from birth. 
Using this cohort, we also estimated the cumulative incidence of the different types of 
substance misuse outcomes for individuals with and without TS/CTD using Kaplan-Meier 
survival estimates under the assumption of no competing risks (estimated as 1 minus the 
Kaplan-Meier estimate of survival function). 
For aim 2, we repeated the main analyses excluding different groups of comorbid 
psychiatric disorders, one at a time, to establish the extent to which the association between 
TS/CTD and different types of substance misuse outcomes was explained by psychiatric 
comorbidity. 
For aim 3, we investigated the associations between TS/CTD and substance misuse 
in a subsample of full siblings within the cohort, identified as individuals who share both 
biological parents. We used Cox proportional hazard regression models stratified by sibling 
clusters, which rule out all factors constant within full siblings (i.e., on average 50% of 
genetic factors and shared environmental influences as, for example, parental 
socioeconomic status) (25,26). Such within-family fixed effects models (27) use information 
from clusters with discordance in the exposure by comparing the individual with TS/CTD with 
their unaffected siblings. We excluded monozygotic twins from the analyses. 
Due to the small number of cases, alcohol/drug-related deaths were not separately 
addressed in the analyses for aims 2 and 3. Statistical analyses were conducted between 
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October 10, and December 20, 2019 with Stata version 14 (StataCorp LP). SAS, version 9 




The study cohort included 14,277,199 individuals with a median length of follow-up of 25.6 
years (interquartile range: 12.7-40.7). Altogether, 7,832 individuals were diagnosed with 
TS/CTD between 1973 and 2013, of which 5,977 were men (76.3%) and 1,855 were women 
(23.7%). The median age at first TS/CTD diagnosis registration was 13.4 years (interquartile 
range: 10.0-21.8) in the total cohort, and 12.3 years (interquartile range: 9.5-16.9) in those 
with follow-up from birth. 
 
Risk of alcohol- or drug-related disorders, criminal convictions, and deaths 
Individuals with TS/CTD had 3.11 (adjusted for sex and birth year, 95% CI: 2.94-3.29) times 
greater risk of any subsequent substance misuse outcome, compared to the unaffected 
general population (Table 1). Specifically, TS/CTD were associated with an increased risk of 
alcohol-related disorder (adjusted hazard ratio [aHR]=3.45, CI: 3.19-3.72), any drug-related 
disorders (aHR=6.84, CI: 6.32-7.40), substance-related criminal convictions (aHR=2.56, CI: 
2.36-2.77), and substance-related death (aHR=2.54, CI: 1.83-3.52). The highest relative risk 
estimates were for the disorders due to stimulants (aHR=9.60, 95% CI: 8.28-11.14) and 
sedatives (aHR=9.04, 95% CI: 8.03-11.17).  
Analyses stratified by sex indicated that men with TS/CTD had a higher relative risk 
of alcohol-related disorder than the corresponding risk estimated for women with TS/CTD, 
whereas women had a higher relative risk of drug-related disorders (Table 1). When looking 
at specific drug-related disorders, estimates for all types of drugs (except for sedatives) were 
9 
 
higher in women, but confidence intervals were non-overlapping only for disorders due to 
cannabis. The relative risk of criminal convictions in individuals with TS/CTD was also higher 
in women than men with TS/CTD, as suggested by the non-overlapping CIs. 
In analyses limited to those with follow-up from birth, the risks for different alcohol- 
and drug-related outcomes attenuated slightly, but were overall very similar to the main 
analyses (Table S4). We estimated the cumulative incidence of different substance misuse 
outcomes in the same subsample (Figure 1). The cumulative incidence of alcohol-related 
disorders in individuals diagnosed with TS/CTD exceeded 20% by age 41 (9% in the general 
population) and was 26% for drug-related disorders (4% in the general population). The 
cumulative incidence of substance-related convictions was 20% in TS/CTD individuals (6% 
in the general population). For substance-related deaths, the cumulative incidence reached 
slightly over 1% by age 41 in those with TS/CTD (less than 0.5% in the general population). 
Differences between individuals with TS/CTD and unaffected individuals in the incidence of 
alcohol-related disorders, drug-related disorders, and substance-related criminal convictions 
were evident by age 16, and for substance-related deaths by age 33 (non-overlapping 95% 
CIs). 
 
Role of psychiatric comorbidities 
As expected, there was extensive psychiatric comorbidity in the TS/CTD cohort with 71.6% 
of individuals with a record of at least one psychiatric disorder (Table S5). ADHD was the 
most common comorbidity (46% of the cohort), followed by pervasive developmental 
disorders (25.7%) and anxiety disorders (25.4%). Exclusion of different groups of psychiatric 
comorbidities, one at the time, resulted in negligible attenuation in the estimates, with the 
exception of anxiety disorders, and particularly ADHD (Table 2). Based on non-overlapping 
CIs in the estimates, excluding individuals with ADHD and anxiety disorders significantly 
decreased, but did not eliminate, the risk of different substance misuse outcomes in 
individuals with TS/CTD. The elevated risk of substance misuse outcomes persisted even 
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The cohort included 2,789,875 families with at least two full siblings, of which 5,310 were 
discordant for TS/CTD. We observed a marked attenuation in the magnitude of the 
associations between TS/CTD and substance misuse outcomes, compared to the estimates 
from the main analyses (Table 3), but the risks for any substance misuse outcome, alcohol-
related disorder, any drug-related disorder, and substance-related criminal convictions were 





To our knowledge, this is the first study to prospectively investigate the association between 
TS/CTD and subsequent substance misuse outcomes. The main findings were that 
individuals with TS/CTD were at increased risk of subsequent alcohol-related disorders, 
drug-related disorders, substance-related criminal convictions, and substance-related 
deaths, even after controlling for unmeasured familial confounders and accounting for 
psychiatric comorbidities. In particular, compared to the unaffected general population, 
individuals with TS/CTD had nearly a 7-fold increased risk of any drug-related disorder 
(including cannabis, opioids, sedatives, and stimulants), over a 3-fold increased risk of 
alcohol-related disorder, and a 2.5-fold increased risk of both substance-related criminal 
convictions and substance-related deaths. 
For the sub-cohort followed from birth, the expected cumulative incidence of alcohol-
related disorders in individuals with TS/CTD exceeded 20% by age 41 (end of the follow-up 
period), reached 26% for drug-related disorders, and 20% for substance-related convictions. 
The corresponding figures in the general population were 9%, 4%, and 6%, respectively, in 
line with recent Danish studies, (28,29). While substance-related deaths were rare in the 
TS/CTD cohort (about 1%), they were still significantly more common than in the general 
population (less than 0.5% during the same follow-up period). Higher incidence of alcohol- or 
drug-related disorders and criminal convictions in individuals with TS/CTD was already 
evident by age 16. These results strongly suggest that regular screening for substance use 
should be an important aspect of the routine clinical management of these patients, even in 
pediatric and child psychiatry settings. 
While the risk of substance misuse was elevated both in men and in women with 
TS/CTD, we also observed some noteworthy sex differences. In particular, men with 
TS/CTD had a higher relative risk of alcohol-related disorders compared to women with 
TS/CTD, whereas women had a higher relative risk of drug-related disorders, particularly 
cannabis use disorders, and criminal convictions. However, these findings do not reflect 
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absolute differences between men and women, but rather the lower baseline risk of 
substance misuse outcomes among women in the general population. In terms of absolute 
risks, men and women with TS/CTD had largely similar prevalences of substance-related 
outcomes. 
A second aim of the study was to explore whether the risk of substance misuse in 
individuals with TS/CTD could be explained by psychiatric comorbidities. This is important 
because many psychiatric disorders are associated with alcohol/drug-related outcomes 
(10,11,30). In general, the exclusion of different groups of psychiatric comorbidities, one at 
the time, did not significantly alter the magnitude of the estimates, although this risk was 
attenuated when ADHD and anxiety disorders were excluded. Specifically, individuals 
without comorbid ADHD still had a 4 times higher risk of drug-related disorders, over 2 times 
higher risk of alcohol-related disorders, and 1.6 times higher risk of substance-related 
criminal convictions. Therefore, TS/CTD are associated with increased risk of substance 
misuse outcomes in their own right, but individuals with comorbid ADHD seem to be at 
particularly high risk. This is unsurprising given the known association between ADHD and 
harms caused by alcohol and drugs (31-33). 
A third aim of the study was to shed some light on the potential mechanisms behind 
the observed associations. In the sibling comparison analyses, the magnitude of the risk 
estimates approximately halved. This degree of attenuation is compatible with a shared 
familial liability between TS/CTD and substance misuse outcomes. Indeed, there may be 
pleiotropic genetic effects (12,13) and/or shared environmental risk factors (e.g., 
socioeconomic status) that may partially influence both the TD/CTD and alcohol- or drug-
related disorders. Future family co-aggregation or twin studies are needed to quantify the 
extent to which genetic and environmental risk factors are shared across these disorders. 
Nevertheless, the risk of alcohol- or drug-related disorders and criminal convictions 
remained statistically significant in the sibling comparisons. That is, siblings affected by 
TS/CTD still had significantly elevated risk of substance misuse outcomes, compared with 
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their unaffected siblings. Because sibling comparisons account for only 50% of genetic 
influences, most of the observed associations between TS/CTD and substance misuse may 
still be genetically driven, but other potential causal mechanisms may be at play, such as the 
possibility that patients with TS/CTD use alcohol or drugs to cope with their symptoms, in 
line with a self-medication hypothesis. The literature is sparse but some reports describe 
patients self-medicating with alcohol or marijuana and experiencing marked reductions of 
tics and associated symptoms (14), triggering promising new experimental research into the 
potential efficacy of cannabinoids in the treatment of tic disorders (34). 
 
Strengths and Limitations 
The main strengths of the current study are the large, population-based sample of 
individuals with TS/CTD, the long follow-up spanning up to 41 years, the high validity of the 
diagnostic codes, (24) the use of nationwide registers with prospective and uniformed data 
collection which minimizes the risk of selection, recall, and report biases, and the use of a 
sibling design which takes into account unobserved familial confounding potentially 
contributing to the observed associations. 
Some important limitations are worth discussing. First, due to the help-seeking nature 
of the TS/CTD cohort, the results may not generalize to milder or transient forms of tic 
disorders that may not require or seek contact with the health services. Nevertheless, the 
individuals with TS/CTD included in our cohort are very similar to those described in the 
international literature, and thus our results are likely to generalize to patients seen in 
specialist clinics around the world (4). Similarly, the coverage of the alcohol- and drug-
related disorders cases is incomplete because the patient register only captures individuals 
with a severe enough clinical presentation to require treatment in specialist inpatient and 
outpatient services. In Sweden, less severe cases are often treated at the primary care level  
(35) which is not covered by the NPR, and treatment underutilization for substance use 
problems is common. 
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Second, although the diagnoses of TS/CTD and substance misuse outcomes were 
recorded independently several years apart, we cannot rule out a degree of surveillance 
bias, whereby various outcomes due to alcohol or drugs may be more likely to be detected in 
individuals who are already in the health system due to TS/CTD. This limitation was 
somewhat mitigated by the inclusion of information from the Crime Register and the Cause 
of Death Register, which are independent from healthcare.  
Third, while the validity and reliability of the ICD codes for TS/CTD are excellent, the 
validity of the SUD codes has not yet been formally examined. However, studies from other 
Nordic patient registers suggest adequate agreement between registered SUD diagnoses 
and diagnoses based on structured interviews by external examiners (36).  
Fourth, we assumed that the majority of TS/CTD cases occur in early childhood, 
even if the diagnosis was only recorded later in life, and thus TS/CTD precedes substance 
misuse. In rare instances, substance misuse may have occurred before the onset of TS/CTD 
but, strictly speaking, TS/CTD should not be diagnosed if the tics are thought to be the direct 
result of a substance (e.g., cocaine). 
 
Conclusions and clinical implications 
TS/CTD are associated with subsequent alcohol and drug use disorders, and related 
outcomes, independently of psychiatric comorbidity and familial factors shared between 
siblings. The results have clear implications for the clinical management of these patients 
and strongly suggest that screening for drug and alcohol use should become part of the 
standard clinical routines, particularly in patients with comorbid ADHD. The results also 
highlight the importance of implementing preventive and early intervention strategies to 
preclude the onset and minimize the consequences of substance misuse in this patient 
group. However, it is important to note that the majority of individuals with TS/CTD do not 
have substance misuse problems, and that a TS/CTD diagnosis should not be automatically 
equated with problematic alcohol- or drug use. If the patient reports using substances, 
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clinicians should carefully assess whether the diagnostic criteria for a substance use 
disorder are met to avoid misdiagnosis, as some patients may use substances, such as 
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Table 1. Prevalence and relative risk of substance misuse outcomes among individuals with Tourette 
syndrome or chronic tic disorder, compared with unaffected individuals from the general population 
and stratified by sex. 
 
 Individuals, no. (%)   
Substance misuse 
Tourette syndrome 











Any substance misuse outcomes*, all 1,241 (15.9) 972,349 (6.8) 3.11 (2.94-3.29) 
Men 966 (16.2) 667,439 (9.3) 3.30 (3.09-3.51) 
Women 275 (14.8) 304,910 (4.3) 3.73 (3.31-4.20) 
Alcohol-related disorder#, all 658 (8.4) 545,903 (3.8) 3.45 (3.19-3.72) 
Men 494 (8.3) 331,072 (4.6) 4.53 (4.14-4.95) 
Women 164 (8.8) 214,831 (3.0) 2.94 (2.52-3.43) 
Any drug-related disorder§, all 627 (8.0) 178,112 (1.3) 6.84 (6.32-7.40) 
Men 466 (7.8) 99,425 (1.4) 6.45 (5.89-7.07) 
Women 161 (8.7) 78,687 (1.1) 8.14 (6.95-9.52) 
  Disorders due to cannabis 161 (2.1) 30,016 (0.2) 5.03 (4.31-5.88) 
  Men 133 (2.2) 23,459 (0.3) 4.77 (4.02-5.66) 
  Women 28 (1.5) 6,557 (0.1) 9.31 (6.42-13.50) 
  Disorders due to opioids 142 (1.8) 39,883 (0.3) 6.38 (5.41-7.53) 
  Men 107 (1.8) 23,943 (0.3) 6.11 (5.04-7.39) 
  Women 35 (1.9) 15,940 (0.2) 8.09 (5.81-11.28) 
  Disorders due to sedatives 281 (3.6) 73,576 (0.5) 9.04 (8.03-10.17) 
  Men 193 (3.2) 33,215 (0.5) 9.56 (8.29-11.02) 
  Women 88 (4.7) 40,361 (0.6) 8.86 (7.17-10.94) 
  Disorders due to stimulants 178 (2.3) 44,223 (0.3) 9.60 (8.28-11.14) 
  Men 132 (2.2) 27,469 (0.4) 8.62 (7.26-10.24) 
  Women 46 (2.5) 16,754 (0.2) 13.21 (9.86-17.71) 
  Disorders due to other substances 361 (4.6) 77,117 (0.5) 7.34 (6.61-8.15) 
  Men 286 (4.8) 49,619 (0.7) 7.17 (6.37-8.07) 
  Women 75 (4.0) 27,498 (0.4) 9.01 (7.16-11.34) 
Substance-related convictions†, all 616 (7.9) 467,241 (3.3) 2.56 (2.36-2.77) 
Men 551 (9.2) 408,439 (5.7) 2.51 (2.31-2.73) 
Women 65 (3.5) 58,802 (0.8) 4.16 (3.26-5.32) 
Substance-related deaths‡, all 38 (0.5) 90,850 (0.6) 2.54 (1.83-3.52) 
Men NA NA NA 
Women NA NA NA 
   
Note: NA = Sex-specific results not reported due to small number of cases. 
*Any substance misuse outcomes include alcohol-related disorder, any drug-related disorder, 
substance-related convictions, and substance-related deaths.  
# Alcohol-related disorders include the diagnoses of mental and behavioral disorders due to alcohol, 
alcohol-related somatic conditions, or poisonings by alcohol. 
§ Any drug-related disorders include the diagnoses of mental and behavioral disorders due to 
psychoactive drugs, drug-related somatic conditions, or poisonings by drugs. 
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† Substance-related convictions include convictions of driving under the influence of alcohol or drugs 
and violations of the Narcotic Drugs Act [SFS 1968:64] such as possession, manufacturing, 
trafficking, or sales of narcotics. 
‡ Substance-related deaths include the causes of death due to mental and behavioral disorders due to 
alcohol or other psychoactive drugs, alcohol- or drug-related somatic conditions, or poisonings by 




Table 2. Risk of substance misuse outcomes in individuals with Tourette syndrome or chronic tic disorder, compared with unaffected 
individuals from the general population, excluding psychiatric comorbidities. 
 

















































































































Note: The results for substance-related deaths are not reported separately due to underpowered analysis. 
* Any substance misuse outcomes include alcohol-related disorder, any drug-related disorder, substance-related convictions, and substance-related deaths.  
# Alcohol-related disorders include the diagnoses of mental and behavioral disorders due to alcohol, 
alcohol-related somatic conditions, or poisonings by alcohol. 
§ Any drug-related disorders include the diagnoses of mental and behavioral disorders due to psychoactive drugs, drug-related somatic conditions, or 
poisonings by drugs. 
† Substance-related convictions include convictions of driving under the influence of alcohol or drugs and violations of the Narcotic Drugs Act [SFS 1968:64] 





Table 3. Sibling comparison for the risk of substance misuse outcomes. 
 
  HR (95% CI) adjusted for sex and birth year 
 















Note: The results for substance-related deaths are not reported separately due to underpowered 
analysis. 
* Any substance misuse outcomes include alcohol-related disorder, any drug-related disorder, 
substance-related convictions, and substance-related deaths.  
# Alcohol-related disorders include the diagnoses of mental and behavioral disorders due to alcohol, 
alcohol-related somatic conditions, or poisonings by alcohol. 
§ Any drug-related disorders include the diagnoses of mental and behavioral disorders due to 
psychoactive drugs, drug-related somatic conditions, or poisonings by drugs. 
† Substance-related convictions include convictions of driving under the influence of alcohol or drugs 
and violations of the Narcotic Drugs Act [SFS 1968:64] such as possession, manufacturing, 






Figure Titles and Legends 
 
Figure 1. Cumulative incidence under the assumption of no competing risks estimated as 1 
– the Kaplan-Meier estimate of survival function (with 95% CIs) for different substance 
misuse outcomes among individuals with Tourette syndrome (TS) or chronic tic disorder 
(CTD) and unaffected individuals from the general population in the subsample of individuals 
followed up from birth (n= 5,219,597). Alcohol = alcohol-related disorders; Drugs = drug-
related disorders; Crimes = substance-related criminal convictions; Deaths = substance-
related deaths 
 
 
